Organon & Co. (NYSE: OGN) announced on November 12, 2026, that a pooled post hoc analysis of its Phase 3 ADORING 1 and ADORING 2 trials found favourable treatment responses with VTAMA (tapinarof) cream, 1%, across several patient subgroups with moderate-to-severe atopic dermatitis. The analysis, scheduled for presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting on November 14, examined disease severity, itch, affected body surface area, disease duration and previous systemic treatment history.
The findings build on the pivotal trials that supported the United States Food and Drug Administration’s December 2024 approval of VTAMA for atopic dermatitis in adults and children aged two years and older. Unlike the original confirmatory efficacy analyses, the new investigation retrospectively examines subgroups defined by clinical characteristics and treatment history. Its main contribution is additional information about consistency of observed responses within the studied population rather than evidence supporting a new indication or regulatory approval.
The pooled dataset included 813 participants randomised to once-daily tapinarof cream or vehicle for eight weeks. Organon reported favourable Eczema Area and Severity Index, investigator-assessed disease severity and itch responses across the evaluated subgroups. However, the company did not disclose complete subgroup sample sizes or formal treatment-by-subgroup interaction analyses in its announcement, limiting the strength of conclusions about differences between patient categories.
What do the pooled ADORING 1 and ADORING 2 results reveal about VTAMA efficacy?
The ADORING 1 and ADORING 2 trials were randomised, vehicle-controlled Phase 3 studies evaluating once-daily VTAMA cream in patients with moderate-to-severe atopic dermatitis. Both trials used an eight-week treatment period and assessed changes in skin disease severity and symptoms. Their original results established statistically significant efficacy on the prespecified primary endpoint, supporting the medicine’s regulatory approval.
The primary endpoint was treatment success on the Validated Investigator Global Assessment for Atopic Dermatitis, defined as clear or almost clear skin with at least a two-grade improvement from baseline. In ADORING 1, 45.4% of participants receiving VTAMA achieved this outcome at Week 8, compared with 13.9% receiving vehicle. ADORING 2 reported corresponding response rates of 46.4% and 18.0%.
These results provide the confirmatory efficacy foundation for the approved treatment. The new pooled analysis examines whether responses appear consistent across groups with different baseline characteristics, including the extent of skin involvement and duration of disease. Such analyses can be useful for clinical interpretation, although they do not carry the same evidentiary weight as prospectively designed subgroup comparisons.
Organon reported that VTAMA-treated participants generally achieved higher EASI75 response rates than vehicle-treated participants across the evaluated categories. EASI75 represents an improvement of at least 75% from baseline in the Eczema Area and Severity Index, a measure combining the extent and severity of atopic dermatitis. It provides a useful assessment of disease improvement but does not necessarily mean complete clearance.
The company also reported favourable responses in investigator global assessment and patient-reported itch. Observing similar directions of treatment effect across different measures can strengthen confidence that a medicine’s benefit is not limited to a single endpoint. Nevertheless, the precision of individual subgroup estimates depends on their sample sizes and the statistical methods used.
The study therefore offers supportive evidence concerning the breadth of VTAMA’s observed treatment responses. It does not demonstrate that every subgroup responds equally well, nor does it establish that baseline characteristics have no effect on treatment outcomes.
How does baseline body surface area influence observed tapinarof responses?
The new analysis divided participants according to the proportion of body surface area affected by atopic dermatitis at baseline. This distinction is clinically relevant because patients may experience similar inflammatory disease processes across substantially different amounts of affected skin. The extent of involvement can influence treatment burden and the practical application of topical medicines.
Among participants with less than 10% body surface area involvement, 57.8% of VTAMA-treated patients achieved EASI75 at Week 8, compared with 32.2% receiving vehicle. For participants with at least 10% involvement, the corresponding response rates were 64.4% and 23.2%. Both categories showed a higher observed response rate with active treatment.
The investigator global assessment results also favoured VTAMA. Response rates were 53.9% versus 22.0% in participants with less than 10% body surface area involvement and 46.0% versus 15.2% in those with greater involvement. These findings suggest that beneficial treatment effects were observed across the two baseline categories.
However, differences in response rates between body surface area subgroups should not be interpreted as proof that VTAMA performs better in one category than another. Establishing treatment-effect modification would require an appropriate statistical comparison, including consideration of baseline characteristics and uncertainty around the estimates. The announcement does not provide sufficient information for such a conclusion.
The relationship between disease extent and topical treatment also has practical implications. Patients with more extensive skin involvement may require larger quantities of cream and more time to complete application. Clinical efficacy must therefore be considered alongside treatment adherence, product use and the ability to maintain a suitable routine.
The new analysis does not establish that every patient with extensive atopic dermatitis can achieve satisfactory control using topical therapy alone. Individual treatment requirements depend on disease characteristics, prior response and other clinical considerations. The findings are best viewed as additional evidence that treatment responses were observed across the studied range of baseline skin involvement.
Why does disease duration matter when assessing VTAMA treatment outcomes?
Atopic dermatitis is a chronic inflammatory skin condition that can follow different clinical courses over time. Some patients develop symptoms early in life and experience recurrent disease, while others have shorter documented histories or periods of improvement. Duration of disease can therefore provide useful context when evaluating treatment responses.
Organon’s analysis divided participants into those with disease duration of zero to five years and those with a history of at least six years. In the shorter-duration subgroup, 70.0% of participants receiving VTAMA achieved EASI75 at Week 8, compared with 31.8% receiving vehicle. Among participants with longer disease duration, the corresponding response rates were 58.8% and 21.7%.
The 70.0% response rate is the highest EASI75 figure highlighted in the company’s selected subgroup results. However, it applies to a particular retrospectively defined patient category and should not be presented as the overall response rate for VTAMA. It also should not be interpreted as evidence that shorter disease duration predicts superior benefit without a formal assessment of subgroup differences.
Investigator-assessed responses followed the same general direction. Participants with disease duration of zero to five years recorded response rates of 53.2% with VTAMA and 17.6% with vehicle, while the corresponding figures for those with at least six years of disease were 45.3% and 16.7%. These findings provide further evidence of treatment activity in both categories.
The relevance to clinical practice lies in whether treatment benefit appears confined to patients with relatively recent disease. The available results do not suggest such a restriction within the evaluated dataset, but they are insufficient to establish that disease duration has no influence on clinical response. Differences in underlying disease characteristics and treatment history may also affect observed outcomes.
Longer-term control remains a separate question. An eight-week response cannot determine how patients with longstanding disease will respond over several years, whether treatment requirements change or how frequently symptoms recur. Those issues require evidence from longer follow-up and appropriately designed studies.
What does the analysis show about patients previously treated with systemic eczema medicines?
Previous treatment history is particularly relevant in atopic dermatitis because patients may move between topical medicines, systemic therapies and biologic treatments as their disease changes. Patients who have received systemic therapy may differ from treatment-naive patients in disease severity, prior treatment response and other clinical characteristics. Examining these groups can help determine whether a topical medicine shows activity across different treatment histories.
Organon reported an EASI75 response rate of 64.3% with VTAMA among participants with previous systemic atopic dermatitis treatment, compared with 3.8% receiving vehicle. Among participants without previous systemic treatment, the corresponding figures were 62.4% and 28.4%. Both categories showed numerically higher response rates with VTAMA.
The particularly low vehicle response in the previously systemically treated subgroup creates a large apparent treatment difference. However, the announcement does not provide the number of participants underlying that 3.8% estimate or sufficient information about its statistical precision. Small comparator groups can produce unstable percentages, making detailed subgroup denominators important before drawing stronger conclusions.
The analysis also does not establish that VTAMA is superior to systemic medicines or appropriate as a replacement for them. The comparison was between topical tapinarof and vehicle, not between tapinarof and a biologic, oral immunomodulator or another active systemic treatment. Previous use of systemic medication is a patient characteristic, not an active treatment comparator.
Investigator global assessment results again favoured VTAMA. Response rates were 45.7% versus 7.7% among participants with previous systemic treatment and 48.4% versus 18.3% among those without such a history. The findings suggest that treatment effects were observed in both groups, although conclusions about their relative magnitude remain limited.
For clinicians, the data may support consideration of the approved product within a broader range of treatment histories. Nevertheless, the evidence does not define the optimal treatment sequence, establish efficacy following failure of every systemic therapy or identify patients who would benefit most from switching. Those decisions require information beyond this retrospective subgroup analysis.
How do the itch findings complement the skin severity results?
Itch is one of the most burdensome symptoms of atopic dermatitis and can disrupt sleep, concentration and daily activities. Improvements in visible skin disease are therefore not necessarily sufficient to capture the full treatment experience. Patient-reported itch measures can provide complementary information about symptomatic benefit.
The new analysis used the Peak Pruritus Numeric Rating Scale to assess itch responses. In the body surface area subgroups, reported response rates with VTAMA were 61.3% and 58.6%, compared with 26.1% and 35.8% for vehicle. These findings indicate favourable patient-reported itch responses across both categories.
Disease duration analyses showed a similar general pattern. VTAMA-treated participants recorded itch response rates of 64.9% in the shorter-duration subgroup and 56.1% in those with longer disease histories. The corresponding vehicle rates were 30.6% and 35.2%.
Among participants with previous systemic treatment, the itch response rates were 55.0% with VTAMA and 20.8% with vehicle. Participants without previous systemic treatment recorded corresponding rates of 60.0% and 35.3%. These findings suggest that symptomatic improvement was observed across different treatment histories.
Interpretation requires attention to the population included in the itch analysis. The original pivotal programme assessed a clinically relevant improvement of at least four points among eligible participants aged 12 years and older with sufficient baseline itch severity. This is not the same denominator as the entire population aged two years and older enrolled in the studies.
Consequently, the itch percentages should not be generalised to every child or every patient included in the pooled analysis. The reported findings are supportive of symptomatic benefit within the relevant assessed population, but the absence of detailed subgroup denominators limits more granular interpretation.
What are the limitations of Organon’s post hoc Phase 3 analysis?
The central methodological limitation is that the new analysis was conducted after the original pivotal trials rather than serving as a prospectively specified confirmatory comparison for every subgroup. Post hoc analyses can identify patterns and provide clinically useful context, but they are also vulnerable to chance findings and imbalances between groups. Their conclusions should therefore remain proportionate to the study design.
Pooling data from ADORING 1 and ADORING 2 increases the number of participants available for analysis and can improve the precision of some estimates. However, pooling does not automatically resolve uncertainty associated with smaller subgroups. The size and baseline characteristics of each category remain important when evaluating response rates.
The analysis also examines several outcomes across multiple subgroup definitions. When numerous comparisons are performed, some numerical differences can arise by chance. Without a clearly described statistical testing framework and appropriate adjustment where required, the observed differences should not be described as independently confirmed subgroup effects.
The original randomised trials provide strong evidence supporting the efficacy of VTAMA for its approved indication. The post hoc findings are best interpreted as supportive analyses examining the consistency of those established results. They cannot extend the authorised population or establish treatment superiority over products that were not included as comparators.
The eight-week study duration imposes another limitation. Atopic dermatitis frequently requires long-term disease management, and short-term responses do not establish sustained remission, reduced treatment burden or long-term comparative effectiveness. Additional evidence from longer studies and clinical practice remains relevant to those questions.
What does the safety profile reveal about the use of VTAMA in atopic dermatitis?
Organon reported that VTAMA was generally well tolerated in the pivotal programme, with commonly reported treatment-emergent adverse events including folliculitis, headache, upper respiratory tract infection and nasopharyngitis. The company’s announcement did not provide new comprehensive subgroup-specific safety analyses. Consequently, the additional efficacy findings should not be interpreted as demonstrating equivalent safety across every patient category.
The United States prescribing information also identifies several adverse reactions observed during the atopic dermatitis clinical programme, including respiratory tract infections, folliculitis, headache, asthma, vomiting, ear infection and other events. Their reported occurrence does not establish that each event was necessarily caused by treatment, but the label provides important information for assessing tolerability.
Tapinarof acts through the aryl hydrocarbon receptor, a mechanism distinct from topical corticosteroids. This gives the medicine a different pharmacological profile, although a non-steroidal designation does not establish that it is safer or more effective than other topical treatments. Comparative conclusions require appropriate studies with relevant active treatment groups.
The approved indication includes adults and children aged two years and older with atopic dermatitis. That authorisation is supported by the pivotal evidence package, but safety and efficacy have not been established for children younger than two years. The separate plaque psoriasis indication applies to adults and should not be broadened to include paediatric psoriasis.
As the medicine is used in routine practice, longer-term information will help clarify treatment patterns, tolerability and outcomes across different patient populations. The current subgroup analysis contributes mainly to understanding efficacy consistency rather than providing a new basis for changing the product’s established safety assessment.
How could the new VTAMA findings influence Organon’s dermatology strategy?
Organon acquired Dermavant Sciences in October 2024, bringing VTAMA into its pharmaceutical portfolio shortly before the United States Food and Drug Administration approved the atopic dermatitis indication. The acquisition expanded Organon’s presence in immunodermatology and provided a commercially available non-steroidal topical product with two distinct authorised indications.
The new analysis may support medical education by providing more detailed information about responses among patients with different baseline characteristics. Such findings can help clinicians interpret the original clinical programme and understand the range of participants in whom treatment activity was observed. However, commercial promotion and clinical decision-making must remain consistent with the approved label and the limitations of the evidence.
The commercial environment for topical atopic dermatitis treatment is competitive. Available therapeutic approaches include topical corticosteroids, topical calcineurin inhibitors, phosphodiesterase-4 inhibitors and other non-steroidal options, alongside systemic therapies for patients requiring broader disease control. VTAMA’s differentiation depends on its mechanism, approved indication, efficacy, tolerability, practical use and access arrangements.
Patient affordability and reimbursement may also influence uptake. Even when a treatment demonstrates efficacy in a controlled trial, prescribing decisions can be affected by insurance formularies, prior authorisation requirements and patient out-of-pocket costs. The new subgroup data do not address these economic barriers or establish cost-effectiveness.
Organon’s corporate position adds another layer of strategic context. Sun Pharmaceutical Industries Limited announced a definitive agreement in April 2026 to acquire Organon for $14 per share in cash, with an enterprise valuation of approximately $11.75 billion. The proposed acquisition remains subject to completion, and the companies have identified early 2027 as the expected closing period.
That transaction could eventually influence how Organon’s dermatology portfolio is managed within a larger pharmaceutical organisation. However, the clinical interpretation of VTAMA’s subgroup data is independent of the proposed ownership change. Any commercial benefits from portfolio integration remain contingent on transaction completion and subsequent execution.
What will determine the clinical significance of the new VTAMA subgroup findings?
The most useful contribution of the new analysis is additional evidence that treatment responses were observed across several patient categories represented in the pivotal studies. The consistency of the direction of treatment effects across skin severity, itch and clinical history provides supportive information for an already approved medicine. It does not establish that every subgroup has the same probability of response or that the treatment performs equally well under all clinical circumstances.
More detailed reporting of subgroup sizes, confidence intervals and statistical methods would help clinicians assess how precisely the response rates have been estimated. Such information is particularly relevant for categories with very low comparator response rates or potentially small populations. Without those details, numerical differences between subgroups should be interpreted cautiously.
Long-term clinical evidence will also remain important. The original ADORING programme included a 48-week open-label extension study, providing a separate opportunity to investigate treatment experience beyond the initial eight-week randomised period. Observational studies can further contribute information about adherence and effectiveness in routine practice, although they cannot replace controlled comparisons where causal conclusions are required.
For Organon, the new results strengthen the evidence narrative surrounding VTAMA without creating a new regulatory milestone. For dermatologists, their value lies in offering a more detailed picture of treatment responses across patients with different disease characteristics and prior treatment histories.
The ultimate measure of VTAMA’s contribution to atopic dermatitis care will be how effectively its established clinical benefits translate into sustained disease control under real-world conditions. The latest pooled analysis supports the consistency of the pivotal trial findings, but questions concerning treatment sequencing, long-term outcomes and comparative effectiveness will require further evidence beyond these post hoc results.
